MedTrace Logo

Urinary Proteomics Combined With Home Blood Pressure Telemonitoring for Health Care Reform

NCT04299529 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2020-03-06

No results posted yet for this study

Summary

UPRIGHT-HTM will compare risk stratification, treatment efficiency and health economic outcomes of a diagnostic approach based on home blood pressure telemonitoring combined with urinary proteomic profiling with home blood pressure telemonitoring alone

Conditions

  • Protein Deregulation
  • Blood Pressure
  • Health Care Utilization
  • Cost Effectiveness
  • Patient Empowerment

Interventions

DIAGNOSTIC_TEST

In-vitro urinary diagnostic test

Urinary proteomic profiling (UPP) using established multidimensional urinary markers for progression to CKD (CKD273), left ventricular dysfunction (HF1 and HF2) and coronary heart disease (CAD238 and ACSP75) - in-vitro test certified in Germany and by extension in the EU (DE/CA09/0829/IVD/001, DE/CA09/0829/IVD/005).

Sponsors & Collaborators

  • Alliance for the Promotion of Preventive Medicine

    collaborator UNKNOWN

  • KU Leuven

    lead OTHER

Principal Investigators

  • Lutgarde Thijs, MSc · University of Leuven

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-01
Primary Completion
2025-12-31
Completion
2026-07-31

Countries

  • Belgium
  • Denmark
  • Germany
  • Greece
  • Nigeria
  • Poland
  • Slovenia
  • South Africa
  • Uruguay

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04299529 on ClinicalTrials.gov